Locally Advanced or Metastatic Breast Cancer

Oncology
1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

MediLink Therapeutics
MediLink TherapeuticsChina - Suzhou
1 program
1
YL202 should be intravenously infusedPhase 21 trial
Active Trials
NCT06439771RecruitingEst. Jul 2028
E
EisaiChina - Liaoning
2 programs
EribulinN/A1 trial
Eribulin mesylateN/A1 trial
Active Trials
NCT03027245Completed353Est. May 2022
NCT03437083Completed340Est. Jun 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
MediLink TherapeuticsYL202 should be intravenously infused
EisaiEribulin mesylate
EisaiEribulin

Clinical Trials (3)

Total enrollment: 693 patients across 3 trials

NCT06439771MediLink TherapeuticsYL202 should be intravenously infused

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Start: Apr 2024Est. completion: Jul 2028
Phase 2Recruiting
NCT03437083EisaiEribulin mesylate

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Start: Jan 2018Est. completion: Jun 2018340 patients
N/ACompleted

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy

Start: Oct 2016Est. completion: May 2022353 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 693 patients
2 companies competing in this space